Scarica l'app Stockscreener
36.72
1.29%
-0.48
Dopo l'orario di chiusura:
36.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Cogent Biosciences, Inc. $COGT Shares Bought by Candriam S.C.A. - MarketBeat
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - Investing News Network
New bezuclastinib data in systemic mastocytosis to debut at AAAAI - Stock Titan
Support Test: Is Cogent Biosciences Inc forming a double bottomWatch List & Short-Term Trading Alerts - baoquankhu1.vn
(COGT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Federated Hermes Inc. Purchases 93,223 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Is FDA Breakthrough Status And Rapid Review For Bezuclastinib Reshaping The Case For Cogent Biosciences (COGT)? - Sahm
Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News - Sahm
Commit To Buy Cogent Biosciences At $25, Earn 17.2% Using Options - Nasdaq
Optimize Financial Inc Buys New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus - Yahoo Finance
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) - Finviz
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Cut to Sell at Wall Street Zen - MarketBeat
Strs Ohio Has $596,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (COGT) Stock Analysis: A Biotech Powerhouse with 34.79% Upside Potential - DirectorsTalk Interviews
Fairmount Funds Management LLC Increases Stake in Cogent Bioscie - GuruFocus
Why Is Pfizer Stock Rising Tuesday? - Sahm
Cogent Biosciences announcse U.S. BTD for bezuclastinib - Yahoo Finance
Cogent Biosciences Gains Breakthrough Therapy Designation For Bezuclastinib Combination In GIST - Nasdaq
(COGT) Risk Channels and Responsive Allocation - Stock Traders Daily
Cogent Biosciences stock rises after FDA grants breakthrough therapy status By Investing.com - Investing.com Nigeria
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag - Benzinga
Cogent Biosciences (COGT) Gains FDA Breakthrough Therapy Designa - GuruFocus
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - The Manila Times
New GIST combo cuts progression risk by 50% in Cogent trial - Stock Titan
Retail Surge: What is the long term forecast for Cogent Biosciences Inc stockJuly 2025 Earnings & Precise Swing Trade Alerts - baoquankhu1.vn
Real-Time FDA Review Of Bezuclastinib Combo In GIST Might Change The Case For Investing In Cogent Biosciences (COGT) - Sahm
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial - TipRanks
Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Director Fairmount Funds Management Llc Sells 3,500,000 Shares - MarketBeat
Fairmount funds sells Cogent Biosciences (COGT) shares worth $127.4 million - Investing.com Canada
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib ComboHas The Bull Case Changed? - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Cogent Biosciences (C - GuruFocus
Cogent Biosciences Initiates New Drug Application Submission for Bezuclastinib Under Real-Time Oncology Review - marketscreener.com
FDA Greenlights Cogent Biosciences' New Drug Application for GIS - GuruFocus
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - The Manila Times
Cogent Biosciences to Initiate New Drug Application - GlobeNewswire
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT - MarketBeat
What makes Cogent Biosciences Inc. stock attractive todayQuarterly Profit Review & Expert Verified Movement Alerts - bollywoodhelpline.com
HC Wainwright is bullish on Cogent Biosciences, Inc. (COGT) - MSN
Geopolitics Watch: What are Cogent Biosciences Incs recent SEC filings showingShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
Cogent Biosciences, Inc. (COGT): Investor Outlook on a Biotech Innovator with a 28% Upside Potential - DirectorsTalk Interviews
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - Sahm
(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1%Still a Buy? - MarketBeat
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - Investing News Network
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - MSN
Cogent Biosciences Announces Anticipated 2026 Commercial - GlobeNewswire
Cancer drug maker lays out 2026 plans for new treatments and trials - Stock Titan
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Finviz
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):